Apolipoprotein-b synthesis inhibitors

PCT No. PCT/EP95/04111 Sec. 371 Date Apr. 9, 1997 Sec. 102(e) Date Apr. 9, 1997 PCT Filed Oct. 19, 1995 PCT Pub. No. WO96/13499 PCT Pub. Date May 9, 1996The present invention provides novel compounds of formula the N-oxides, the stereochemically isomeric forms thereof, and the pharmaceutically accep...

Full description

Saved in:
Bibliographic Details
Main Authors EYCKEN VAN DER LUC ALFONS LEO, BACKX LEO JACOBUS JOZEF, DE CHAFFOY DE COURCELLES DIDIER ROBERT GUY GABRIEL, HEERES JAN, HENDRICKX ROBERT JOZEF MARIA
Format Patent
LanguageEnglish
Published 04.07.2003
Edition7
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:PCT No. PCT/EP95/04111 Sec. 371 Date Apr. 9, 1997 Sec. 102(e) Date Apr. 9, 1997 PCT Filed Oct. 19, 1995 PCT Pub. No. WO96/13499 PCT Pub. Date May 9, 1996The present invention provides novel compounds of formula the N-oxides, the stereochemically isomeric forms thereof, and the pharmaceutically acceptable acid addition salts thereof, wherein A and B taken together form a bivalent radical of formula: -N=CH- (a), -CH=N- (b), -CH2-CH2- (c), -CH=CH- (d), -C(=O)-CH2- (e), -CH2-C(=O)- (f); R1 is hydrogen, C1-6alkyl, or halo; R2 is hydrogen or halo; R3 is hydrogen; C1-8alkyl; C3-6cycloalkyl or C1-8alkyl substituted with hydroxy, oxo, C3-6cycloalkyl or aryl. Het is five- or six-membered optionally substituted heterocyclic ring. The use as a medicine, especially as a lipid lowering agent is disclosed as well as pharmaceutical compositions and processes for preparing compounds and compositions.
Bibliography:Application Number: CY20020000004